Neoadjuvant/adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585

被引：0

作者：

Shitara, Kohei

Bang, Yung-Jue

Wyrwicz, Lucjan S.

Rha, Sun Young

Oshima, Takashi

Di Bartolomeo, Maria

Park, Young-Kyu

Lonardi, Sara

Weber, Patricio Eduardo Yanez

Yen, Chia-Jui

Metges, Jean-Philippe

Garrido, Marcelo

Moehler, Markus H.

Pelles-Avraham, Sharon

Yong, Wei-Peng

Spallanzani, Andrea

Jensen, Erin

Krishnan, Radha

Shih, Chie-Schin

Al-Batran, Salah-Eddin

机构：

[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[2] Seoul Natl Univ, Grad Sch, Coll Med, Seoul, South Korea

[3] Maria Sklodowska Curie Natl Canc Res Inst, Warsaw, Poland

[4] Yonsei Univ, Coll Med, Seoul, South Korea

[5] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[7] Chonnam Natl Univ, Med Sch, Hwasun, South Korea

[8] IRCCS, Veneto Inst Oncol IOV, Padua, Italy

[9] Univ La Frontera, James Lind Canc Res Ctr, Temuco, Chile

[10] Natl Cheng Kung Univ, Tainan, Taiwan

[11] CHU Brest, Inst Cancerol & Hematol ARPEGO Network, Brest, France

[12] Pontificia Univ Catolica, Clin San Carlos Apoquindo, Santiago, Chile

[13] Johannes Gutenberg Univ Clin, Mainz, Germany

[14] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[15] Natl Univ Canc Inst Singapore NCIS, Singapore, Singapore

[16] Univ Hosp Modena, Modena, Italy

[17] Merck & Co Inc, Rahway, NJ USA

[18] UCT Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4073

引用

页数：1